UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Britain Courts Anthropic Amid US Defense Department Dispute 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Apple Turns 50: From Garage Startup to AI Crossroads 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
SEATTLE, Oct. 05, 2016 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release third quarter 2016 financial results after the close of trading on Wednesday, November 2, 2016. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.
Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers. Please reference Conference ID: 91871843. To listen to a live webcast, please visit the investor relations section of the company’s website at: www.nanostring.com.
A replay of the call will be available beginning November 2, 2016 at 7:30pm ET through 7:30pm ET on November 3, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 91871843. The webcast will also be available on the Company’s website for one year following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications [email protected] Phone: 206-602-1768
